No Data
No Data
Byondis Appoints Louis Denis, M.D., as Chief Medical Officer
RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $13
A. G. P. Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14
Verastem Price Target Lowered to $14 From $20 at Alliance Global Partners
Express News | Corrected-Verastem Inc: Qtrly Adj Shr Loss $0.88 (Not '$0.71')
Verastem Cuts FY24 EPS View to $4.17-$4.23 From $4.25-$4.35, Consensus $4.28